

EQA round: AP1/23 - Antithrombotic Agents

Deadline: 31.3.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

| Test Sample Group | [unit] | RoM | SD | CV [%] | N _{tot} | N _{out} | Comparability | | | | | | N _{eva} | N _{suc} | S _{rel} [%] | |
|-------------------------------------|--------|------|-----|-----------|------------------|------------------|---------------|-----------------|------------------|-----|------|------|------------------|------------------|-------------------------|----|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | | | |
| Set 1 | | | | | | | | | | | | | | | | |
| (108) Apixaban | [µg/L] | | | | 39 | | | | | | | | | 39 | 37 | 95 |
| Sample A1 | | 63,9 | 9 | 14 | 39 | | CVP | 63,9 | 3,6 | 25% | 47,9 | 79,9 | | 39 | 37 | 95 |
| (38) IL | | 72,3 | 4,2 | 5,9 | 13 | 0 | | | | | | | | 13 | | |
| (94) Stago | | 58 | 12 | 20 | 6 | 0 | | | | | | | | 6 | | |
| (149) Siemens (Dade, BN, Dimension) | | 60,5 | 6,7 | 11 | 9 | 0 | | | | | | | | 9 | | |
| (179) Siemens | | 60,5 | 6,7 | 11 | 5 | 1 | | | | | | | | 5 | | |
| (193) HYPHEN BioMed | | 58 | 9,1 | 16 | 6 | 0 | | | | | | | | 6 | | |
| Sample B1 | | 281 | 20 | 7,2 | 39 | | CVP | 281 | 8 | 25% | 210 | 352 | | 39 | 38 | 97 |
| (38) IL | | 294 | 11 | 3,9 | 13 | 0 | | | | | | | | 13 | | |
| (94) Stago | | 277 | 23 | 8,3 | 6 | 0 | | | | | | | | 6 | | |
| (149) Siemens (Dade, BN, Dimension) | | 281 | 19 | 6,6 | 9 | 0 | | | | | | | | 9 | | |
| (179) Siemens | | 253 | 42 | 17 | 5 | 1 | | | | | | | | 5 | | |
| (193) HYPHEN BioMed | | 258 | 24 | 9,2 | 6 | 0 | | | | | | | | 6 | | |
| Set 2 | | | | | | | | | | | | | | | | |
| (109) Dabigatran | [µg/L] | | | | 36 | | | | | | | | | 36 | 34 | 94 |
| Sample A2 | | 48,3 | 4,4 | 9,2 | 36 | | CVP | 48,3 | 1,8 | 30% | 33,8 | 62,8 | | 36 | 34 | 94 |
| (38) IL | | 48,3 | 2,3 | 4,7 | 12 | 0 | | | | | | | | 12 | | |
| (149) Siemens (Dade, BN, Dimension) | | 42,5 | 5,2 | 12 | 8 | 0 | | | | | | | | 8 | | |
| (179) Siemens | | 51 | 3 | 5,8 | 5 | 1 | | | | | | | | 5 | | |
| (193) HYPHEN BioMed | | 50,8 | 5,9 | 12 | 11 | 0 | | | | | | | | 11 | | |
| Sample B2 | | 215 | 22 | 10 | 36 | | CVP | 215 | 9 | 30% | 150 | 280 | | 36 | 35 | 97 |
| (38) IL | | 209 | 9,7 | 4,6 | 12 | 0 | | | | | | | | 12 | | |
| (149) Siemens (Dade, BN, Dimension) | | 197 | 19 | 9,4 | 8 | 0 | | | | | | | | 8 | | |
| (179) Siemens | | 210 | 5,2 | 2,5 | 5 | 1 | | | | | | | | 5 | | |
| (193) HYPHEN BioMed | | 243 | 18 | 7,3 | 11 | 0 | | | | | | | | 11 | | |
| Set 3 | | | | | | | | | | | | | | | | |
| (110) Rivaroxaban | [µg/L] | | | | 45 | | | | | | | | | 45 | 44 | 98 |
| Sample A3 | | 80,1 | 6 | 7,4 | 45 | | CVP | 80,1 | 2,2 | 25% | 60 | 101 | | 45 | 44 | 98 |
| (38) IL | | 83,7 | 4,7 | 5,6 | 15 | 0 | | | | | | | | 15 | | |
| (94) Stago | | 74,4 | 3,9 | 5,2 | 6 | 0 | | | | | | | | 6 | | |
| (149) Siemens (Dade, BN, Dimension) | | 78,1 | 5,5 | 7,1 | 10 | 0 | | | | | | | | 10 | | |
| (179) Siemens | | 80 | 3 | 3,7 | 6 | 1 | | | | | | | | 6 | | |
| (193) HYPHEN BioMed | | 80,8 | 12 | 15 | 7 | 0 | | | | | | | | 7 | | |
| Other | | | | | 1 | 0 | | | | | | | | 1 | | |
| | | | | | | | 1x 162 | | | | | | | | | |
| Sample B3 | | 292 | 27 | 9,1 | 45 | | CVP | 292 | 9,8 | 25% | 219 | 365 | | 45 | 44 | 98 |
| (38) IL | | 284 | 13 | 4,4 | 15 | 0 | | | | | | | | 15 | | |
| (94) Stago | | 292 | 6,1 | 2,1 | 6 | 0 | | | | | | | | 6 | | |
| (149) Siemens (Dade, BN, Dimension) | | 284 | 31 | 11 | 10 | 0 | | | | | | | | 10 | | |
| (179) Siemens | | 291 | 43 | 15 | 6 | 1 | | | | | | | | 6 | | |
| (193) HYPHEN BioMed | | 327 | 16 | 4,8 | 7 | 0 | | | | | | | | 7 | | |
| Other | | | | | 1 | 0 | | | | | | | | 1 | | |
| | | | | | | | 1x 162 | | | | | | | | | |